Global Zopiclone Market Size By Type (Tablet(7.5mg), Tablet(3.75mg)), By Application (Retail Pharmacies, Hospital Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Zopiclone Market was valued at USD 1.1 billion in 2023 and is anticipated to reach USD 1.9 billion by 2031, growing at a CAGR of 7.0% during the forecast period from 2023 to 2031. Zopiclone, a non-benzodiazepine hypnotic agent, is widely prescribed for the short-term treatment of insomnia. Its rising demand is driven by the increasing prevalence of sleep disorders, growing stress levels, and the expanding geriatric population worldwide. Additionally, the expanding awareness about mental health and sleep hygiene is propelling the growth of this market.

Drivers:

1. Rising Incidence of Insomnia and Sleep Disorders:

Modern lifestyles, characterized by high stress levels, irregular working hours, and excessive screen exposure, are significantly contributing to sleep-related disorders. This has led to a growing dependence on pharmacological interventions like Zopiclone.

2. Aging Population:

With age, sleep patterns become disrupted, leading to increased demand for hypnotic agents such as Zopiclone. The expanding geriatric demographic globally is a key factor supporting market growth.

3. Growing Awareness and Diagnosis:

Increased healthcare access and awareness about the importance of quality sleep are enabling more individuals to seek treatment, further boosting the Zopiclone market.

Restraints:

1. Risk of Dependency and Abuse:

Long-term use of Zopiclone is associated with dependence, tolerance, and withdrawal symptoms, which has led to its regulation and restricted usage, especially in developed nations.

2. Availability of Alternatives:

The market faces competitive pressure from other sleep-inducing drugs and behavioral therapies such as cognitive behavioral therapy for insomnia (CBT-I), which is often preferred due to its non-pharmacological approach.

Opportunity:

1. Expansion in Emerging Economies:

Countries in Asia-Pacific and Latin America are witnessing increased healthcare spending, better diagnostics, and growing awareness, opening new avenues for market expansion.

2. Development of Safer Formulations:

Innovation in drug delivery methods, such as extended-release or abuse-deterrent formulations, provides an opportunity for pharmaceutical companies to differentiate their offerings and ensure safer consumption.

Market by System Type Insights:

By formulation, the Tablet segment held the dominant share in 2023, accounting for the majority of Zopiclone prescriptions. Tablets are widely preferred due to their ease of use, affordability, and rapid onset of action. However, oral sprays and sublingual formulations are emerging as fast-growing segments, catering to patients with swallowing difficulties or those requiring quicker absorption.

Market by End-Use Insights:

The Hospitals segment emerged as the leading end-use segment in 2023, owing to the high volume of inpatient care and psychiatric evaluations. Retail pharmacies, however, are expected to witness significant growth due to the ease of drug availability and increasing outpatient diagnoses of insomnia.

Market by Regional Insights:

North America held the largest share in the global Zopiclone market in 2023, driven by high prevalence of insomnia, well-established healthcare infrastructure, and proactive mental health awareness campaigns. The Asia-Pacific region is projected to register the highest CAGR during the forecast period, driven by rapid urbanization, lifestyle changes, and increasing mental health awareness in countries such as India and China.

Competitive Scenario:

Key players operating in the Global Zopiclone Market include Sanofi, Teva Pharmaceuticals, Mylan N.V., Lupin Limited, Torrent Pharmaceuticals, Aurobindo Pharma, Apotex Inc., and Intas Pharmaceuticals. These companies are focusing on regional expansion, drug approvals, and development of generics and safer formulations. Notable developments include:

2023: Teva Pharmaceuticals launched a new generic version of Zopiclone in multiple European countries following regulatory clearance.

2024: Lupin Limited announced the development of a sublingual Zopiclone tablet aimed at geriatric patients.

2025: Mylan N.V. entered into a distribution partnership to expand its Zopiclone offerings in Southeast Asia.

Scope of Work – Global Zopiclone Market

Report Metric Details

Market Size (2023) USD 1.1 Billion

Projected Market Size (2031) USD 1.9 Billion

CAGR (2023–2031) 7.0%

Market Segments By Formulation (Tablets, Sublingual), End-use (Hospitals, Retail Pharmacies), Region

Growth Drivers Rising insomnia cases, Aging population, Greater awareness of mental health

Opportunities Emerging markets, Safer drug formulations

Key Market Developments:

2023: Teva Pharmaceuticals launched a generic Zopiclone variant in France and Spain.

2024: Lupin Limited introduced a geriatric-friendly sublingual formulation.

2025: Aurobindo Pharma received FDA approval for its Zopiclone extended-release tablets aimed at reducing dependency risks.

FAQs:

1) What is the current market size of the Global Zopiclone Market?

The Global Zopiclone Market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Zopiclone Market?

The market is primarily driven by the rising prevalence of insomnia and other sleep disorders globally.

3) Which is the largest region during the forecast period in the Global Zopiclone Market?

North America is expected to maintain its dominance due to advanced healthcare infrastructure and high diagnosis rates.

4) Which segment accounted for the largest market share in the Global Zopiclone Market?

The tablet formulation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Zopiclone Market?

Major players include Sanofi, Teva Pharmaceuticals, Mylan N.V., Lupin Limited, Aurobindo Pharma, and Apotex Inc.